Tiss'You
Financial Overview – 2026 Partial (September 30th)

Tiss'You SRL closed the first nine months of 2026 with the strongest results in its history, extending the growth path of recent years.

Revenues amounted to €4.86 million, an increase of +27% over the same period of 2025, with international customers accounting for about three quarters of sales.
Profitability improved further: EBITDA reached €2.55 million, a margin above 50% of revenues.

The company is fully self-financed: €2.41 million of Cash & Equivalents and no bank debt.

Key Highlights

- Global Reach: our distributor network keeps expanding, bringing Tiss'You products to a growing number of countries.
- Efficiency: costs grew far more slowly than revenues, lifting margins.
- Science-Driven Innovation: ongoing R&D investments, including AI-based peptide discovery, keep enriching our regenerative medicine pipeline.

Looking Ahead to Year-End 2026
Based on the performance to date, Tiss'You expects to close 2026 with new record levels of both revenues and profitability.

Our focus for the coming months will be on:

- Opening new international markets.
- Increasing production capacity at our San Marino facility.
- Bringing new products from the R&D pipeline to market.

These results confirm Tiss'You as a fast-growing, financially solid player in the regenerative medicine sector, ready for the next stage of its development.

Tiss'You SRL
Dr. Paolo Fattori, PhD
CEO